Gemcitabine and radiosensitization in human tumor cells

Area of Science:

• Oncology
• Radiochemistry
• Molecular Biology

Background:

• Gemcitabine is a nucleoside analogue with established clinical activity against solid tumors.
• Its cytotoxic effects stem from inhibiting DNA replication and reducing cellular dNTP pools.
• These properties suggest potential radiosensitizing capabilities.

Purpose of the Study:

• To evaluate gemcitabine's ability to enhance X-radiation-induced cytotoxicity.
• To investigate the metabolic mechanisms underlying gemcitabine's radiosensitizing effects.

Main Methods:

• Gemcitabine's radiosensitizing potential was assessed in various cancer cell lines (colorectal, pancreatic, breast, lung, head and neck).
• Cellular metabolic effects, including gemcitabine metabolite levels and dNTP pools, were analyzed under radiosensitizing conditions.
• Timing of administration relative to irradiation was optimized.

Main Results:

• Gemcitabine demonstrated potent radiosensitization across multiple tumor cell lines, particularly when administered 2 hours before irradiation.
• Radiosensitization occurred at non-cytotoxic concentrations and was dose- and duration-dependent.
• Key metabolic changes included accumulation of gemcitabine triphosphate and a decrease in cellular dATP, with dATP reduction correlating with enhanced radiosensitivity.

Conclusions:

• Gemcitabine is a potent radiosensitizer effective at concentrations significantly lower than typical plasma levels.
• The drug's ability to decrease cellular dATP pools is a key factor in its radiosensitizing effect.
• Findings support the clinical development of gemcitabine in combination with radiation therapy for various cancers.